The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV89.6P

Journal of Virological Methods

Volumn 112, Issue 1-2, 2003, Pages 121-128

  Yoshimura, Kazuhisa ^a   Ido, Eiji ^b   Akiyama, Hisashi ^b   Kimura, Tetsuya ^a   Aoki, Manabu ^a   Suzuki, Hajime ^b   Mitsuya, Hiroaki ^a   Hayami, Masanori ^b   Matsushita, Shuzo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Animal model; Antiretroviral therapy; Ki67+; Memory CD8+ T cells; Proviral DNA; SHIV89.6P

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; KI 67 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VIRUS DNA; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG SENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MONKEY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN;

ANIMALIA; MACACA; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0242348839     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(03)00201-5     Document Type: Article

References (37)

1. Antia R., Halloran M.E. Recent developments in theories of pathogenesis of AIDS. Trends Microbiol. 4:(7):1996;282-285.
2. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:(4):2002;379-385.
3. + T cell homeostasis and function in advanced HIV disease. Science. 277:(5322):1997;112-116.
4. Badley A.D., Parato K., Cameron D.W., Kravcik S., Phenix B.N., Ashby D., Kumar A., Lynch D.H., Tschopp J., Angel J.B. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 6:(5):1999;420-432.
5. Carrillo A., Stewart K.D., Sham H.L., Norbeck D.W., Kohlbrenner W.E., Leonard J.M., Kempf D.J., Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:(9):1998;7532-7541.
6. + T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J. Infect. Dis. 185:(11):2002;1672-1676.
7. Clapham P.R., Weiss R.A., Dalgleish A.G., Exley M., Whitby D., Hogg N. Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology. 158:(1):1987;44-51.
8. Clavel F., Guetard D., Brun-vezinet F., Chamaret S., Rey M.A., Santos-ferreira M.O., Laurent A.G., Dauguet C., Katlama C., Rouzioux C. Isolation of a new human retrovirus from West African patients with AIDS. Science. 233:(4761):1986;343-346.
9. Endo Y., Igarashi T., Nishimura Y., Buckler C., Buckler-White A., Plishka R., Dimitrov D.S., Martin M.A. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74:(15):2000;6935-6945.
10. Enose Y., Ui M., Miyake A., Suzuki H., Uesaka H., Kuwata T., Kunisawa J., Kiyono H., Takahashi H., Miura T., Hayami M. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology. 298:(2):2002;306-316.
11. + T cell population with memory rather than naive cells. Antiviral Res. 39:(3):1998;163-173.
12. Gougeon M.L., Lecoeur H., Sasaki Y. Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Immunol. Lett. 66:(1-3):1999;97-103.
13. Haigwood N.L. Progress and challenges in therapies for AIDS in nonhuman primate models. J. Med. Primatol. 28:(4-5):1999;154-163.
14. Hellerstein M., Hanley M.B., Cesar D., Siler S., Papageorgopoulos C., Wieder E., Schmidt D., Hoh R., Neese R., Macallan D., Deeks S., McCune J.M. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:(1):1999;83-89.
15. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA. 98:(2):2001;658-663.
16. Kimura T., Yoshimura K., Nishihara K., Maeda Y., Matsumi S., Koito A., Matsushita S. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J. Infect. Dis. 185:(1):2002;53-60.
17. Kostrikis L.G., Touloumi G., Karanicolas R., Pantazis N., Anastassopoulou C., Karafoulidou A., Goedert J.J., Hatzakis A. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J. Virol. 76:(20):2002;10099-10108.
18. Le Grand R., Clayette P., Noack O., Vaslin B., Theodoro F., Michel G., Roques P., Dormont D. An animal model for antilentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res. Hum. Retroviruses. 10:(10):1994;1279- 1287.
19. Le Grand R., Vaslin B., Larghero J., Neidez O., Thiebot H., Sellier P., Clayette P., Dereuddre-Bosquet N., Dormont D. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS. 14:(12):2000;1864-1866.
20. Le Grand, R., Vaslin, B., Benlhassan, K., Thiebot, H., Dereuddre-Bosquet, N., Clayette, P., Dormont, D., 2002. Post-exposure prophylaxis with HAART in macaques exposed to pathogenic SIV or SHIV. XIV International AIDS Conference.
21. Li J., Lord C.I., Haseltine W., Letvin N.L., Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquired Immune Defic. Syndr. 5:(7):1992;639-646.
22. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., Miyakawa T., Aoki M., Fukushima D., Mitsuya H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276:(37):2001;35194-35200.
23. Margolick J.B., Munoz A., Donnenberg A.D., Park L.P., Galai N., Giorgi J.V., O'Gorman M.R., Ferbas J. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat. Med. 1:(7):1995;674-680.
24. Mezzaroma I., Carlesimo M., Pinter E., Alario C., Sacco G., Muratori D.S., Bernardi M.L., Paganelli R., Aiuti F. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS. 13:(10):1999;1187-1193.
25. Nath B.M., Schumann K.E., Boyer J.D. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol. 8:(9):2000;426-431.
26. Nathanson N., Hirsch V.M., Mathieson B.J. The role of nonhuman primates in the development of an AIDS vaccine. AIDS. 13:(Suppl. A):1999;S113-S120.
27. O'Doherty U., Swiggard W.J., Jeyakumar D., McGain D., Malim M.H. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J. Virol. 76:(21):2002;10942-10950.
28. Ogg G.S., Jin X., Bonhoeffer S., Moss P., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Hurley A., Markowitz M., Ho D.D., McMichael A.J., Nixon D.F. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73:(1):1999;797-800.
29. Pakker N.G., Notermans D.W., de Boer R.J., Roos M.T., de Wolf F., Hill A., Leonard J.M., Danner S.A., Miedema F., Schellekens P.T. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4:(2):1998;208-214.
30. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., Sodroski J., Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS- like disease after in vivo passage in rhesus monkeys. J. Virol. 70:(10):1996;6922-6928.
31. Reimann K.A., Li J.T., Voss G., Lekutis C., Tenner-Racz K., Racz P., Lin W., Montefiori D.C., Lee-Parritz D.E., Lu Y., Collman R.G., Sodroski J., Letvin N.L. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70:(5):1996;3198-3206.
32. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J. Exp. Med. 187:(8):1998;1295-1303.
33. Sodora D.L., Milush J.M., Ware F., Wozniakowski A., Montgomery L., McClure H.M., Lackner A.A., Marthas M., Hirsch V., Johnson R.P., Douek D.C., Koup R.A. Decreased levels of recent thymic emigrants in peripheral blood of simian immunodeficiency virus-infected macaques correlate with alterations within the thymus. J. Virol. 76:(19):2002;9981-9990.
34. Tang Y., Villinger F., Staprans S.I., Amara R.R., Smith J.M., Herndon J.G., Robinson H.L. Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges. J. Virol. 76:(20):2002;10147-10154.
35. Thiebot H., Louache F., Vaslin B., de Revel T., Neildez O., Larghero J., Vainchenker W., Dormont D., Le Grand R. Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection. J. Virol. 75:(23):2001;11594-11602.
36. Ui M., Kuwata T., Igarashi T., Ibuki K., Miyazaki Y., Kozyrev I.L., Enose Y., Shimada T., Uesaka H., Yamamoto H., Miura T., Hayami M. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs. Virology. 265:(2):1999;252-263.
37. Yoshimura K., Kato R., Yusa K., Kavlick M.F., Maroun V., Nguyen A., Mimoto T., Ueno T., Shintani M., Falloon J., Masur H., Hayashi H., Erickson J., Mitsuya H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA. 96:(15):1999;8675-8680.